Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any status in the axilla when neoadjuvant treatment not is considered as an option. The primary aim is to determine the proportion of patients that converts to estrogen receptor (ER) positive breast cancer in the removed breast cancer tissue at surgery.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony potrójnie ujemny rak piersi o średnicy co najmniej 15 mm.
- •Pacjentki w wieku powyżej 18 lat.
- •Rak piersi nie reagujący na hormony (estrogeny i progesteron) ani na czynnik HER2.
- •Brak wcześniejszego leczenia raka piersi.
- •Pacjentki w dobrym ogólnym stanie zdrowia.
- •Prawidłowe wyniki podstawowych badań krwi i narządów.
✗ Disqualifies
- •Pacjentki, które mogą być leczone metodami przedoperacyjnymi (chemioterapia przed operacją).
- •Przyjmowanie innego leczenia przeciwnowotworowego w ciągu ostatnich 14 dni.
- •Niezdolność do przestrzegania zasad badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Barbro Linderholm
Gothenburg, Sweden
Trial contact
Barbro K Linderholm, MD, PhD
Elisabeth Kapocs
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.